| Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More | Frank Vinluan | 10/09/20 | National |
| Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals | Frank Vinluan | 09/14/20 | Seattle |
| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears | Frank Vinluan | 08/14/20 | Europe |
| Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy | Frank Vinluan | 08/11/20 | Europe |
| Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More | Sarah de Crescenzo | 08/07/20 | National |
| GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod | Sarah de Crescenzo | 08/06/20 | National |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| GSK Pays CureVac $328M in mRNA Vaccines Pact—Excluding COVID-19 | Frank Vinluan | 07/20/20 | Europe |
| Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership | Sarah de Crescenzo | 07/09/20 | Boston |
| NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep | Frank Vinluan | 07/09/20 | Philadelphia |
| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance | Frank Vinluan | 06/16/20 | San Francisco |
| Pharma Partnering: Perspectives from Xcelerating Life Sciences Panel | Frank Vinluan | 06/16/20 | Philadelphia |
| GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track | Mandy Jackson | 06/12/20 | National |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| Variant Emerges With $16M to Find “Outlier Humans” to Reveal New Drugs | Sarah de Crescenzo | 05/28/20 | Seattle |
| Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More | Frank Vinluan | 05/22/20 | National |
| HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic | Frank Vinluan | 05/21/20 | Boston |
| BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info | Frank Vinluan | 05/13/20 | New York |
| Pfizer Pays Valneva $130M for a Bite at a Lyme Disease Vaccine | Frank Vinluan | 05/01/20 | Europe |
| Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory | Frank Vinluan | 04/23/20 | Boston |
| Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More | Sarah de Crescenzo | 04/17/20 | National |
| GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year | Frank Vinluan | 04/14/20 | National |
| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months | Frank Vinluan | 04/06/20 | San Francisco |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic | Frank Vinluan | 03/12/20 | Boston |
| Takeda Bases PvP Biologics Buyout on Promising Early Celiac Drug Data | Sarah de Crescenzo | 02/26/20 | San Diego |
